As Wyeth Pharmaceuticals defends itself against antitrust claims in San Francisco Superior Court, its legal battles may lead to a new rule for opting out of class actions.

A class action and an unfair competition suit, which have been coordinated before a San Francisco judge for more than a year, both accuse Wyeth of squelching competition to its drug Premarin, which treats hot flashes and other symptoms of menopause.